Trial Profile
A Double Blind, Randomized, Investigator Initiated Study on Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie (Lobeglitazone) in Patients With Type 2 Diabetes With Inadequate Control on Metformin and DPP-4 Inhibitor Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Aug 2022
Price :
$35
*
At a glance
- Drugs Lobeglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REFIND
- 04 Jan 2022 Status changed from not yet recruiting to completed.
- 17 Dec 2018 New trial record